18F-FDG Cell Labeling May Underestimate Transplanted Cell Homing: More Accurate, Efficient, and Stable Cell Labeling with Hexadecyl-4-[18F]Fluorobenzoate for in Vivo Tracking of Transplanted Human Progenitor Cells by Positron Emission Tomography

Cell therapy is expected to restore perfusion and improve function in the ischemic/infarcted myocardium; however, the biological mechanisms and local effects of transplanted cells remain unclear. To assess cell fate in vivo, hexadecyl-4-[18F]fluorobenzoate (18F-HFB) cell labeling was evaluated for tracking human circulating progenitor cells (CPCs) with positron emission tomography (PET) and was compared to the commonly used 2-[18F]fluoro-2-deoxy-d-glucose (18F-FDG) labeling method in a rat myocardial infarction model. CPCs were labeled with 18F-HFB or 18F-FDG ex vivo under the same conditions. 18F-HFB cell-labeling efficiency (23.4 ± 7.5%) and stability (4 h, 88.4 ± 6.0%) were superior to 18F-FDG (7.6 ± 4.1% and 26.6 ± 6.1%, respectively; p < 0.05). Neither labeling approach significantly altered cell viability, phenotype or migration potential up to 24 h postlabeling. Two weeks after left anterior descending coronary artery ligation, rats received echo-guided intramyocardial injection in the infarct border zone with 18F-HFB-CPCs, 18F-FDG-CPCs, 18F-HFB, or 18F-FDG. Dynamic PET imaging of both 18F-HFB-CPCs and 18F-FDG-CPCs demonstrated that only 16–37% of the initial injection dose (ID) was retained in the injection site at 10 min postdelivery, and remaining activity fell significantly over the first 4 h posttransplantation. The 18F-HFB-CPC signal in the target area at 2 h (23.7 ± 14.7% ID/g) and 4 h (17.6 ± 13.3% ID/g) postinjection was greater than that of 18F-FDG-CPCs (5.4 ± 2.3% ID/g and 2.6 ± 0.7% ID/g, respectively; p < 0.05). Tissue biodistribution confirmed the higher radioactivity in the border zone of 18F-HFB-CPC rats. Immunostaining of heart tissue sections revealed no significant difference in cell retention between two labeled cell transplantation groups. Good correlation with biodistribution results was observed in the 18F-HFB-CPC rats (r = 0.81, p < 0.05). Compared to 18F-FDG, labeling human CPCs with 18F-HFB provides a more efficient, stable, and accurate way to quantify the distribution of transplanted cells. 18F-HFB cell labeling with PET imaging offers a better modality to enhance our understanding of early retention, homing, and engraftment with cardiac cell therapy.

[1]  Michael E. Phelps,et al.  Ex vivo cell labeling with 64Cu–pyruvaldehyde-bis(N4-methylthiosemicarbazone) for imaging cell trafficking in mice with positron-emission tomography , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[2]  M. Ruel,et al.  Comparative effects of mesenchymal progenitor cells, endothelial progenitor cells, or their combination on myocardial infarct regeneration and cardiac function. , 2007, The Journal of thoracic and cardiovascular surgery.

[3]  Winfried Brenner,et al.  111In-labeled CD34+ hematopoietic progenitor cells in a rat myocardial infarction model. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[4]  Ping Zhang,et al.  Radiolabeled Cell Distribution After Intramyocardial, Intracoronary, and Interstitial Retrograde Coronary Venous Delivery: Implications for Current Clinical Trials , 2005, Circulation.

[5]  A. Ganser,et al.  Monitoring of Bone Marrow Cell Homing Into the Infarcted Human Myocardium , 2005, Circulation.

[6]  M. Ruel,et al.  In vitro functional comparison of therapeutically relevant human vasculogenic progenitor cells used for cardiac cell therapy. , 2010, The Journal of thoracic and cardiovascular surgery.

[7]  M. Hoehn,et al.  In Vivo MRI Stem Cell Tracking Requires Balancing of Detection Limit and Cell Viability , 2010, Cell transplantation.

[8]  M. Ruel,et al.  Effects of off-pump versus on-pump coronary artery bypass grafting on function and viability of circulating endothelial progenitor cells. , 2005, The Journal of thoracic and cardiovascular surgery.

[9]  ToyoakiMurohara,et al.  Mobilization of Endothelial Progenitor Cells in Patients With Acute Myocardial Infarction , 2001 .

[10]  M. Ruel,et al.  Generation of CD133+ cells from CD133- peripheral blood mononuclear cells and their properties. , 2006, Cardiovascular research.

[11]  Haruchika Masuda,et al.  Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization , 1999, Nature Medicine.

[12]  S. Canevari,et al.  Comparison of three different methods for radiolabelling human activated T lymphocytes , 1997, European Journal of Nuclear Medicine.

[13]  S. Goldstein,et al.  A simple method for stem cell labeling with fluorine 18. , 2005, Nuclear medicine and biology.

[14]  D. Kuraitis,et al.  Improving cell engraftment with tissue engineering. , 2008, Seminars in thoracic and cardiovascular surgery.

[15]  A. Boyle,et al.  Injection of bone marrow cell extract into infarcted hearts results in functional improvement comparable to intact cell therapy. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[16]  M. Ruel,et al.  Tracking stem cell therapy in the myocardium: applications of positron emission tomography. , 2008, Current pharmaceutical design.

[17]  S. Homma,et al.  Neovascularization of ischemic myocardium by human bone-marrow–derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function , 2001, Nature Medicine.

[18]  C. Murry,et al.  Systems approaches to preventing transplanted cell death in cardiac repair. , 2008, Journal of molecular and cellular cardiology.

[19]  N. Kaji,et al.  Quantum Dots for Labeling Adipose Tissue-Derived Stem Cells , 2009, Cell transplantation.

[20]  Paul Dendale,et al.  Recovery of Regional but Not Global Contractile Function by the Direct Intramyocardial Autologous Bone Marrow Transplantation: Results From a Randomized Controlled Clinical Trial , 2006, Circulation.

[21]  Zhan-Long Ma,et al.  Assessments of Proliferation Capacity and Viability of New Zealand Rabbit Peripheral Blood Endothelial Progenitor Cells Labeled with Superparamagnetic Particles , 2009, Cell transplantation.

[22]  Y. Yoon,et al.  Intramyocardial Transplantation of Autologous Endothelial Progenitor Cells for Therapeutic Neovascularization of Myocardial Ischemia , 2003, Circulation.

[23]  Yan Zhang,et al.  Collagen-Based Matrices Improve the Delivery of Transplanted Circulating Progenitor Cells: Development and Demonstration by Ex Vivo Radionuclide Cell Labeling and In Vivo Tracking With Positron-Emission Tomography , 2008, Circulation. Cardiovascular imaging.

[24]  Stefanie Dimmeler,et al.  Unchain my heart: the scientific foundations of cardiac repair. , 2005, The Journal of clinical investigation.

[25]  K. Poh,et al.  Intramyocardial Transplantation of Autologous CD34+ Stem Cells for Intractable Angina: A Phase I/IIa Double-Blind, Randomized Controlled Trial , 2007, Circulation.

[26]  W. Weber,et al.  Tumor Cell Metabolism Imaging , 2008, Journal of Nuclear Medicine.

[27]  M. Ruel,et al.  From genes to regenerative medicine: approaches in development. , 2008, Circulation research.

[28]  K. Nichols,et al.  PET with FDG-labeled leukocytes versus scintigraphy with 111In-oxine-labeled leukocytes for detection of infection. , 2006, Radiology.

[29]  Joel Price,et al.  Tissue-Engineered Injectable Collagen-Based Matrices for Improved Cell Delivery and Vascularization of Ischemic Tissue Using CD133+ Progenitors Expanded From the Peripheral Blood , 2006, Circulation.

[30]  Winfried Brenner,et al.  Assessment of the Tissue Distribution of Transplanted Human Endothelial Progenitor Cells by Radioactive Labeling , 2003, Circulation.

[31]  S. Gambhir,et al.  Image-guided cardiac cell delivery using high-resolution small-animal ultrasound. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.